{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:46:39Z","timestamp":1775889999269,"version":"3.50.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177093","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T17:37:15Z","timestamp":1495474635000},"page":"e0177093","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study"],"prefix":"10.1371","volume":"12","author":[{"given":"Elie","family":"Azoulay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lautrette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-6734","authenticated-orcid":true,"given":"Stephane","family":"Legriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Max","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Ruckly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Misset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00134-014-3355-z","article-title":"Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later","volume":"40","author":"P Eggimann","year":"2014","journal-title":"Intensive care medicine"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(03)00801-6","article-title":"Epidemiology of Candida species infections in critically ill non-immunosuppressed patients","volume":"3","author":"P Eggimann","year":"2003","journal-title":"The Lancet Infectious diseases"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Extended Prevalence of Infection in ICUSGoI. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"DH Kett","year":"2011","journal-title":"Critical care medicine"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/01.CCM.0000201897.78123.44","article-title":"Invasive candidiasis in the intensive care unit","volume":"34","author":"L Ostrosky-Zeichner","year":"2006","journal-title":"Critical care medicine"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","article-title":"Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study","volume":"38","author":"A Tabah","year":"2012","journal-title":"Intensive care medicine"},{"issue":"Suppl 7","key":"ref6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"OA Cornely","year":"2012","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/514955","article-title":"The impact of candidemia on length of hospital stay, outcome, and overall cost of illness","volume":"27","author":"AM Rentz","year":"1998","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/CCM.0b013e31819daa14","article-title":"Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study","volume":"37","author":"C Leon","year":"2009","journal-title":"Critical care medicine"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1186\/cc10507","article-title":"Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1\u2014>3)-beta-D-glucan assay, Candida score, and colonization index","volume":"15","author":"B Posteraro","year":"2011","journal-title":"Critical care"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"M Morrell","year":"2005","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","article-title":"Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting","volume":"26","author":"L Ostrosky-Zeichner","year":"2007","journal-title":"European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","article-title":"A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization","volume":"34","author":"C Leon","year":"2006","journal-title":"Critical care medicine"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-143-12-200512200-00004","article-title":"Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis","volume":"143","author":"Y Golan","year":"2005","journal-title":"Annals of internal medicine"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","article-title":"Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial","volume":"149","author":"MG Schuster","year":"2008","journal-title":"Annals of internal medicine"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/cid\/ciu074","article-title":"MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting","volume":"58","author":"L Ostrosky-Zeichner","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/1745-6215-14-399","article-title":"EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial","volume":"14","author":"JF Timsit","year":"2013","journal-title":"Trials"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"TJ Walsh","year":"1999","journal-title":"The New England journal of medicine"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1128\/AAC.44.8.2068-2076.2000","article-title":"Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits","volume":"44","author":"TJ Walsh","year":"2000","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"TJ Walsh","year":"2001","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":"Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study","volume":"31","author":"C Cordonnier","year":"2008","journal-title":"International journal of antimicrobial agents"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"J El-Cheikh","year":"2007","journal-title":"Bone marrow transplantation"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"OA Cornely","year":"2007","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/TP.0000000000000393","article-title":"High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis in Patients Undergoing Liver Transplantation: A Prospective Phase II Trial","volume":"99","author":"M Giannella","year":"2015","journal-title":"Transplantation"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","article-title":"Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence","volume":"53","author":"K Ritmeijer","year":"2011","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"F Lanternier","year":"2015","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-003-0993-4","article-title":"High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates","volume":"22","author":"A Juster-Reicher","year":"2003","journal-title":"European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/jac\/dks155","article-title":"European Organization for the Research and Treatment of Cancer\/Mycoses Study Group (EORTC\/MSG) host factors and invasive fungal infections in patients with haematological malignancies","volume":"67","author":"M Hoenigl","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine","volume":"26","author":"JL Vincent","year":"1998","journal-title":"Critical care medicine"},{"issue":"24","key":"ref29","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"JR Le Gall","year":"1993","journal-title":"Jama"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s001340050334","article-title":"Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research","volume":"23","author":"MG Petri","year":"1997","journal-title":"Intensive care medicine"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/109629600750067200","article-title":"The diagnostic value of fungal surveillance cultures in critically ill patients","volume":"1","author":"RK Pelz","year":"2000","journal-title":"Surgical infections"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1097\/01.CCM.0000147726.62304.7F","article-title":"Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients","volume":"32","author":"R Piarroux","year":"2004","journal-title":"Critical care medicine"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00134-002-1540-y","article-title":"Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination","volume":"28","author":"J Garbino","year":"2002","journal-title":"Intensive care medicine"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1086\/319763","article-title":"Prophylactic antifungal therapy in the intensive care unit","volume":"32","author":"JH Rex","year":"2001","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00134-008-1338-7","article-title":"Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis","volume":"35","author":"BP Guery","year":"2009","journal-title":"Intensive care medicine"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"C Cordonnier","year":"2009","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"M Bassetti","year":"2014","journal-title":"Intensive care medicine"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00134-014-3404-7","article-title":"Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?","volume":"40","author":"D Maubon","year":"2014","journal-title":"Intensive care medicine"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3201\/eid1801.110556","article-title":"Candida spp. with acquired echinocandin resistance, France, 2004\u20132010","volume":"18","author":"E Dannaoui","year":"2012","journal-title":"Emerging infectious diseases"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1093\/jac\/dkr394","article-title":"Antifungal use influences Candida species distribution and susceptibility in the intensive care unit","volume":"66","author":"P Fournier","year":"2011","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1439-0507.2006.01222.x","article-title":"Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study","volume":"49","author":"KW Garey","year":"2006","journal-title":"Mycoses"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/030079907X182130","article-title":"High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis","volume":"23","author":"H Chen","year":"2007","journal-title":"Current medical research and opinion"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","article-title":"Candidaemia in Europe: epidemiology and resistance","volume":"27","author":"AM Tortorano","year":"2006","journal-title":"International journal of antimicrobial agents"},{"issue":"12","key":"ref44","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1128\/JCM.43.12.5848-5859.2005","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing","volume":"43","author":"MA Pfaller","year":"2005","journal-title":"Journal of clinical microbiology"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"O Lortholary","year":"2014","journal-title":"Intensive care medicine"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata","volume":"50","author":"MA Pfaller","year":"2012","journal-title":"Journal of clinical microbiology"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"BD Alexander","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1128\/AAC.00136-13","article-title":"Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure","volume":"57","author":"RK Shields","year":"2013","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","author":"D Caillot","year":"2007","journal-title":"Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:43:49Z","timestamp":1692812629000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177093"}},"subtitle":[],"editor":[{"given":"Felipe","family":"Dal Pizzol","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177093","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}